Quest for the right Drug
הלדול דקאנואס HALDOL DECANOAS (HALOPERIDOL AS DECANOATE)
תרופה במרשם
תרופה בסל
נרקוטיקה
ציטוטוקסיקה
צורת מתן:
תוך-שרירי : I.M
צורת מינון:
תמיסה להזרקה : SOLUTION FOR INJECTION
עלון לרופא
מינוניםPosology התוויות
Indications תופעות לוואי
Adverse reactions התוויות נגד
Contraindications אינטראקציות
Interactions מינון יתר
Overdose הריון/הנקה
Pregnancy & Lactation אוכלוסיות מיוחדות
Special populations תכונות פרמקולוגיות
Pharmacological properties מידע רוקחי
Pharmaceutical particulars אזהרת שימוש
Special Warning עלון לרופא
Physicians Leaflet
Adverse reactions : תופעות לוואי
4.8 Undesirable effects The safety of haloperidol decanoate was evaluated in 410 patients who participated in 3 comparator studies (1 comparing haloperidol decanoate versus fluphenazine and 2 comparing the decanoate formulation to oral haloperidol), 9 open label studies and 1 dose response study. Based on pooled safety data from these clinical studies, the most commonly reported adverse reactions were: extrapyramidal disorder (14%), tremor (8%), parkinsonism (7%), muscle rigidity (6%) and somnolence (5%). In addition, the safety of haloperidol was evaluated in 284 haloperidol-treated patients who participated in 3 placebo-controlled clinical studies and in 1295 haloperidol-treated patients who participated in 16 double-blind active comparator-controlled clinical studies. Table 3 lists adverse reactions as follows: • Reported in clinical studies with haloperidol decanoate. • Reported in clinical studies with haloperidol (non-decanoate formulations) and relate to the active moiety. • From postmarketing experience with haloperidol decanoate and haloperidol. Adverse reaction frequencies are based on (or estimated from) clinical trials or epidemiology studies with haloperidol decanoate, and classified using the following convention: Very common: ≥1/10 Common: ≥1/100 to <1/10 Uncommon: ≥1/1,000 to <1/100 Rare: ≥1/10,000 to <1/1,000 Very rare: <1/10,000 Not known: cannot be estimated from the available data. The adverse reactions are presented by System Organ Class and in order of decreasing seriousness within each frequency category. Haldol decanoas_100mg/ml_PI_ 01-2023 Table 3: Adverse reactions System Organ Adverse Reaction Class Frequency Very Common Uncommon Rare Not known Common Blood and Pancytopenia lymphatic Agranulocytosis system Thrombocytopenia disorders Leukopenia Neutropenia Immune Anaphylactic reaction system Hypersensitivity disorders Endocrine Inappropriate antidiuretic disorders hormone secretion Hyperprolactinaemia Metabolic and Hypoglycaemia nutritional disorders Psychiatric Depression Psychotic disorder disorders Insomnia Agitation Confusional state Loss of libido Libido decreased Restlessness Nervous Extrapyramidal Akathisia Akinesia Neuroleptic malignant system disorder Parkinsonism Dyskinesia syndrome disorders Masked facies Dystonia Tardive dyskinesia Tremor Cogwheel rigidity Convulsion Somnolence Hypertonia Bradykinesia Sedation Headache Hyperkinesia Hypokinesia Dizziness Muscle contractions involuntary Motor dysfunction Nystagmus Eye disorders Oculogyric crisis Vision blurred Visual disturbance Cardiac Tachycardia Ventricular fibrillation disorders Torsade de pointes Ventricular tachycardia Extrasystoles Vascular Hypotension disorders Orthostatic hypotension Respiratory, Laryngeal oedema thoracic and Bronchospasm mediastinal Laryngospasm disorders Dyspnoea Gastrointestinal Constipation Vomiting disorders Dry mouth Nausea Salivary hypersecretion Haldol decanoas_100mg/ml_PI_ 01-2023 System Organ Adverse Reaction Class Frequency Very Common Uncommon Rare Not known Common Hepatobiliary Acute hepatic failure disorders Hepatitis Cholestasis Jaundice Liver function test abnormal Skin and Angioedema subcutaneous Dermatitis exfoliative tissue Leukocytoclastic disorders vasculitis Photosensitivity reaction Urticaria Pruritus Rash Hyperhidrosis Musculoskeletal Muscle Rhabdomyolysis and connective rigidity Torticollis tissue disorders Trismus Muscle spasms Muscle twitching Musculoskeletal stiffness Renal and Urinary retention urinary disorders Pregnancy, Drug withdrawal puerperium syndrome neonatal (see and perinatal section 4.6) conditions Reproductive Sexual Priapism system and dysfunction Amenorrhoea breast Galactorrhoea disorders Dysmenorrhoea Menorrhagia Erectile dysfunction Gynaecomastia Menstrual disorder Breast pain Breast discomfort General Injection site Sudden death disorders and reaction Face oedema administration Oedema site conditions Hyperthermia Hypothermia Gait disturbance Injection site abscess Investigations Weight Electrocardiogram QT increased prolonged Weight decreased Electrocardiogram QT prolonged, ventricular arrhythmias (ventricular fibrillation, ventricular tachycardia), torsade de pointes and sudden death have been reported with haloperidol. Class effects of antipsychotics Cardiac arrest has been reported with antipsychotics. Haldol decanoas_100mg/ml_PI_ 01-2023 Cases of venous thromboembolism, including cases of pulmonary embolism and cases of deep vein thrombosis, have been reported with antipsychotics. The frequency is unknown. Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions to the Ministry of Health, according to the National Regulation by using an online form: https://sideeffects.health.gov.il
שימוש לפי פנקס קופ''ח כללית 1994
Chronic schizophrenia. יירשם ע"י רופא עצבים ורופא פסיכיאטר
תאריך הכללה מקורי בסל
01/01/1995
הגבלות
תרופה מוגבלת לרישום ע'י רופא מומחה או הגבלה אחרת
מידע נוסף
עלון מידע לצרכן
16.12.21 - עלון לצרכן אנגלית 31.03.21 - עלון לצרכן עברית 16.12.21 - עלון לצרכן עברית 16.12.21 - עלון לצרכן ערבית 16.03.23 - עלון לצרכן עברית 23.10.23 - עלון לצרכן אנגלית 23.10.23 - עלון לצרכן עברית 23.10.23 - עלון לצרכן ערבית 04.12.11 - החמרה לעלון 09.01.12 - החמרה לעלון 31.03.21 - החמרה לעלון 16.03.23 - החמרה לעלוןלתרופה במאגר משרד הבריאות
הלדול דקאנואס